See more : Software Acquisition Group Inc. III (SWAGU) Income Statement Analysis – Financial Results
Complete financial analysis of Abbott Laboratories (ABT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abbott Laboratories, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Collective Mining Ltd. (CNL.TO) Income Statement Analysis – Financial Results
- QHSLab, Inc. (USAQ) Income Statement Analysis – Financial Results
- Punjab Communications Limited (PUNJCOMMU.BO) Income Statement Analysis – Financial Results
- Atea Pharmaceuticals, Inc. (AVIR) Income Statement Analysis – Financial Results
- Growth Capital Acquisition Corp. (GCAC) Income Statement Analysis – Financial Results
Abbott Laboratories (ABT)
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.11B | 43.65B | 43.08B | 34.61B | 31.90B | 30.58B | 27.39B | 20.85B | 20.41B | 20.25B | 21.85B | 39.87B | 38.85B | 35.17B | 30.77B | 29.53B | 25.91B | 22.48B | 22.34B | 19.68B | 19.68B | 17.68B | 16.29B | 13.75B | 13.18B | 12.48B | 11.88B | 11.01B | 10.01B | 9.16B | 8.41B | 7.85B | 6.88B | 6.16B | 5.38B | 4.94B | 4.39B | 3.81B | 3.36B |
| Cost of Revenue | 17.98B | 19.14B | 18.54B | 15.00B | 13.23B | 12.71B | 12.34B | 9.02B | 8.75B | 9.22B | 10.04B | 15.12B | 15.54B | 14.67B | 13.21B | 12.61B | 11.42B | 9.82B | 10.64B | 8.88B | 9.47B | 8.51B | 7.75B | 6.24B | 5.98B | 5.39B | 5.05B | 4.73B | 4.33B | 3.99B | 3.68B | 3.08B | 2.76B | 2.55B | 2.25B | 2.08B | 1.86B | 1.67B | 1.54B |
| Gross Profit | 22.13B | 24.51B | 24.54B | 19.61B | 18.67B | 17.87B | 15.05B | 11.83B | 11.66B | 11.03B | 11.81B | 24.75B | 23.31B | 20.50B | 17.56B | 16.92B | 14.49B | 12.66B | 11.70B | 10.80B | 10.21B | 9.18B | 8.54B | 7.51B | 7.20B | 7.08B | 6.84B | 6.28B | 5.69B | 5.16B | 4.72B | 4.77B | 4.12B | 3.60B | 3.13B | 2.85B | 2.53B | 2.14B | 1.82B |
| Gross Profit Ratio | 55.18% | 56.15% | 56.97% | 56.65% | 58.53% | 58.45% | 54.96% | 56.73% | 57.13% | 54.47% | 54.05% | 62.08% | 60.00% | 58.30% | 57.06% | 57.29% | 55.92% | 56.33% | 52.36% | 54.86% | 51.86% | 51.90% | 52.42% | 54.61% | 54.64% | 56.77% | 57.54% | 57.03% | 56.79% | 56.38% | 56.18% | 60.81% | 59.85% | 58.53% | 58.19% | 57.82% | 57.65% | 56.17% | 54.19% |
| Research & Development | 2.74B | 2.89B | 2.74B | 2.42B | 2.44B | 2.30B | 2.24B | 1.42B | 1.41B | 1.35B | 1.45B | 4.32B | 4.80B | 3.73B | 2.74B | 2.69B | 2.51B | 2.26B | 1.82B | 1.70B | 1.73B | 1.56B | 1.58B | 1.35B | 1.19B | 1.22B | 1.30B | 1.20B | 1.07B | 963.52M | 880.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.74B | 9.12B | 6.67B | 6.79B | 6.53B | 6.94B | 12.06B | 12.76B | 10.38B | 8.41B | 8.44B | 7.41B | 6.35B | 5.50B | 4.92B | 5.05B | 3.98B | 3.73B | 2.89B | 2.86B | 2.74B | 2.68B | 2.46B | 2.23B | 2.05B | 1.99B | 2.82B | 2.18B | 1.84B | 1.60B | 1.48B | 1.28B | 1.06B | 928.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -495.00K | -817.00K | -324.00K | 96.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.95B | 11.25B | 11.32B | 9.70B | 9.77B | 9.74B | 9.12B | 6.67B | 6.79B | 6.53B | 6.94B | 12.06B | 12.76B | 10.38B | 8.41B | 8.44B | 7.41B | 6.35B | 5.50B | 4.92B | 5.05B | 3.98B | 3.73B | 2.89B | 2.86B | 2.74B | 2.68B | 2.46B | 2.23B | 2.05B | 1.99B | 2.82B | 2.18B | 1.84B | 1.60B | 1.48B | 1.28B | 1.06B | 928.20M |
| Other Expenses | 1.97B | 2.01B | 2.05B | 2.13B | 1.94B | 139.00M | 1.25B | -945.00M | 281.00M | -14.00M | 32.00M | 34.00M | -119.00M | 62.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -138.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -70.00M | 427.80M | 379.00M | 355.90M | 307.30M | 270.90M | 243.70M | 199.50M | 155.80M |
| Operating Expenses | 15.66B | 16.15B | 16.11B | 14.25B | 14.14B | 14.22B | 13.33B | 8.64B | 8.79B | 8.43B | 9.18B | 16.38B | 17.56B | 14.10B | 11.15B | 11.12B | 9.91B | 8.60B | 7.32B | 6.62B | 6.78B | 5.54B | 5.31B | 4.11B | 4.05B | 3.97B | 3.99B | 3.66B | 3.30B | 3.02B | 2.80B | 3.25B | 2.56B | 2.20B | 1.91B | 1.75B | 1.52B | 1.26B | 1.08B |
| Cost & Expenses | 33.63B | 35.29B | 34.65B | 29.25B | 27.37B | 26.93B | 25.66B | 17.67B | 17.54B | 17.65B | 19.22B | 31.50B | 33.10B | 28.77B | 24.36B | 23.74B | 21.34B | 18.42B | 17.96B | 15.50B | 16.26B | 14.05B | 13.06B | 10.35B | 10.03B | 9.36B | 9.03B | 8.40B | 7.63B | 7.01B | 6.48B | 6.33B | 5.32B | 4.75B | 4.16B | 3.84B | 3.38B | 2.93B | 2.62B |
| Interest Income | 385.00M | 183.00M | 43.00M | 46.00M | 94.00M | 105.00M | 124.00M | 99.00M | 105.00M | 77.00M | 67.00M | 79.23M | 85.20M | 105.45M | 137.78M | 201.23M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 637.00M | 375.00M | 490.00M | 500.00M | 576.00M | 721.00M | 780.00M | 332.00M | 58.00M | 73.00M | 90.00M | 513.00M | 530.14M | 553.14M | 382.00M | 528.47M | 593.14M | 292.35M | 153.66M | 149.09M | 146.12M | 205.22M | 234.76B | 23.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.24B | 3.27B | 3.54B | 3.33B | 3.01B | 3.28B | 3.02B | 1.35B | 601.00M | 555.00M | 791.00M | 2.78B | 3.04B | 2.62B | 2.09B | 1.84B | 1.85B | 1.56B | 1.36B | 1.29B | 1.27B | 1.18B | 1.17B | 827.43M | 828.01M | 784.24M | 727.75M | 686.09M | 566.42M | 510.50M | 484.08M | 427.80M | 379.00M | 355.90M | 307.30M | 270.90M | 243.70M | 199.50M | 155.80M |
| EBITDA | 10.61B | 12.38B | 12.74B | 8.79B | 7.77B | 7.12B | 6.13B | 3.07B | 4.83B | 4.22B | 3.45B | 3.50B | 9.26B | 9.14B | 9.49B | 8.22B | 6.43B | 4.25B | 6.22B | 5.61B | 4.20B | 4.30B | 4.39B | 3.40B | 3.98B | 3.90B | 3.56B | 3.30B | 2.95B | 2.65B | 2.41B | 1.95B | 1.94B | 1.76B | 1.53B | 1.37B | 1.25B | 1.08B | 892.90M |
| EBITDA Ratio | 26.44% | 24.50% | 24.95% | 21.94% | 20.87% | 19.51% | 18.08% | 13.38% | 18.37% | 15.51% | 15.80% | 21.08% | 15.08% | 19.30% | 20.82% | 21.20% | 25.41% | 33.72% | 23.92% | 27.28% | 21.54% | 25.87% | 33.77% | 26.56% | 27.68% | 29.46% | 28.54% | 29.05% | 29.16% | 28.61% | 27.38% | 21.50% | 27.41% | 28.02% | 27.53% | 27.03% | 28.27% | 27.62% | 24.92% |
| Operating Income | 6.48B | 8.36B | 8.43B | 5.36B | 4.53B | 3.65B | 1.73B | 3.19B | 2.87B | 2.60B | 2.63B | 8.09B | 5.75B | 6.09B | 6.24B | 5.69B | 4.58B | 2.04B | 4.36B | 3.90B | 3.32B | 3.53B | 1.89B | 3.40B | 3.15B | 3.12B | 2.85B | 2.62B | 2.38B | 2.14B | 1.92B | 1.53B | 1.56B | 1.41B | 1.22B | 1.10B | 1.01B | 878.60M | 737.10M |
| Operating Income Ratio | 16.15% | 19.16% | 19.56% | 15.48% | 14.21% | 11.94% | 6.30% | 15.27% | 14.05% | 12.84% | 12.03% | 20.28% | 14.81% | 17.31% | 20.27% | 19.28% | 17.67% | 9.09% | 19.53% | 19.81% | 16.88% | 19.96% | 11.63% | 24.74% | 23.90% | 24.99% | 23.99% | 23.76% | 23.80% | 23.42% | 22.88% | 19.43% | 22.64% | 22.83% | 22.70% | 22.32% | 22.92% | 23.07% | 21.94% |
| Total Other Income/Expenses | 186.00M | -56.00M | -214.00M | -389.00M | -455.00M | -777.00M | 667.00M | -1.61B | 316.00M | -81.00M | -92.00M | -1.22B | -553.36M | -374.75M | 958.03M | 162.45M | -108.90M | 234.15M | 257.65M | 227.28M | 411.89M | 143.27M | -10.88M | 415.83M | 247.53M | 123.98M | 84.17M | 52.44M | 12.42M | 22.48M | 19.26M | 212.80M | -12.80M | -55.30M | -27.00M | -46.60M | -68.50M | -59.90M | -42.60M |
| Income Before Tax | 6.66B | 8.31B | 8.21B | 4.97B | 4.08B | 2.87B | 2.23B | 1.41B | 3.18B | 2.52B | 2.52B | 6.26B | 5.20B | 5.71B | 7.19B | 5.86B | 4.47B | 2.28B | 4.62B | 4.13B | 3.73B | 3.67B | 1.88B | 3.82B | 3.40B | 3.24B | 2.95B | 2.67B | 2.40B | 2.17B | 1.94B | 1.74B | 1.54B | 1.35B | 1.19B | 1.06B | 937.20M | 818.70M | 694.50M |
| Income Before Tax Ratio | 16.61% | 19.03% | 19.06% | 14.36% | 12.78% | 9.40% | 8.15% | 6.78% | 15.60% | 12.44% | 11.54% | 15.71% | 13.38% | 16.25% | 23.38% | 19.83% | 17.25% | 10.13% | 20.68% | 20.96% | 18.98% | 20.77% | 11.56% | 27.76% | 25.78% | 25.97% | 24.82% | 24.24% | 23.92% | 23.66% | 23.11% | 22.14% | 22.46% | 21.93% | 22.20% | 21.38% | 21.36% | 21.50% | 20.67% |
| Income Tax Expense | 941.00M | 1.37B | 1.14B | 497.00M | 390.00M | 539.00M | 1.88B | 350.00M | 577.00M | 797.00M | 138.00M | 300.00M | 470.00M | 1.09B | 1.45B | 1.12B | 863.33M | 559.62M | 1.25B | 949.76M | 981.18M | 879.71M | 332.76M | 1.03B | 951.13M | 907.37M | 855.48M | 787.52M | 706.62M | 650.01M | 544.10M | 499.70M | 455.50M | 385.00M | 334.40M | 303.40M | 304.60M | 278.20M | 229.20M |
| Net Income | 5.72B | 6.93B | 7.07B | 4.50B | 3.69B | 2.37B | 477.00M | 1.40B | 4.42B | 2.28B | 2.58B | 5.96B | 4.73B | 4.63B | 5.75B | 4.88B | 3.61B | 1.72B | 3.37B | 3.24B | 2.75B | 2.79B | 1.55B | 2.79B | 2.45B | 2.33B | 2.08B | 1.88B | 1.69B | 1.52B | 1.40B | 1.24B | 1.09B | 965.80M | 859.80M | 752.00M | 632.60M | 540.50M | 465.30M |
| Net Income Ratio | 14.27% | 15.88% | 16.42% | 12.99% | 11.56% | 7.74% | 1.74% | 6.71% | 21.68% | 11.28% | 11.79% | 14.95% | 12.17% | 13.15% | 18.68% | 16.53% | 13.92% | 7.64% | 15.10% | 16.44% | 13.99% | 15.80% | 9.52% | 20.27% | 18.56% | 18.71% | 17.50% | 17.09% | 16.87% | 16.56% | 16.64% | 15.78% | 15.83% | 15.68% | 15.98% | 15.23% | 14.42% | 14.20% | 13.85% |
| EPS | 3.30 | 3.94 | 3.97 | 2.52 | 2.07 | 1.35 | 0.27 | 0.95 | 3.00 | 1.51 | 1.66 | 3.78 | 3.01 | 2.99 | 3.72 | 3.16 | 2.34 | 1.12 | 2.17 | 2.07 | 1.76 | 1.79 | 1.00 | 1.80 | 1.59 | 1.52 | 1.35 | 1.21 | 1.06 | 0.93 | 0.84 | 0.74 | 0.64 | 0.56 | 0.49 | 0.42 | 0.35 | 0.29 | 0.25 |
| EPS Diluted | 3.27 | 3.91 | 3.94 | 2.50 | 2.06 | 1.34 | 0.27 | 0.94 | 2.94 | 1.50 | 1.64 | 3.75 | 3.01 | 2.97 | 3.70 | 3.13 | 2.31 | 1.12 | 2.16 | 2.06 | 1.75 | 1.78 | 0.99 | 1.78 | 1.57 | 1.49 | 1.33 | 1.19 | 1.06 | 0.93 | 0.84 | 0.74 | 0.64 | 0.56 | 0.49 | 0.42 | 0.35 | 0.29 | 0.25 |
| Weighted Avg Shares Out | 1.73B | 1.75B | 1.78B | 1.77B | 1.77B | 1.76B | 1.74B | 1.47B | 1.47B | 1.51B | 1.55B | 1.58B | 1.57B | 1.55B | 1.55B | 1.54B | 1.54B | 1.53B | 1.55B | 1.56B | 1.56B | 1.56B | 1.55B | 1.55B | 1.54B | 1.54B | 1.55B | 1.56B | 1.59B | 1.62B | 1.66B | 1.67B | 1.70B | 1.72B | 1.75B | 1.79B | 1.81B | 1.86B | 1.86B |
| Weighted Avg Shares Out (Dil) | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B | 1.77B | 1.75B | 1.48B | 1.51B | 1.53B | 1.57B | 1.59B | 1.57B | 1.56B | 1.56B | 1.56B | 1.56B | 1.54B | 1.56B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.56B | 1.56B | 1.58B | 1.58B | 1.59B | 1.62B | 1.66B | 1.67B | 1.70B | 1.72B | 1.75B | 1.79B | 1.81B | 1.86B | 1.86B |
Jury asked to award more than $6 billion in preterm formula case against Abbott, Reckitt's Mead
A lawyer for a Missouri mother on Wednesday asked a jury to make Abbott and Reckitt's Mead Johnson pay a total of more than $6 billion in the latest trial over claims that the companies' formulas for premature babies caused...
Abbott Laboratories Employees Credit Union ("ALECU") Data Breach - Levi & Korsinsky, LLP Launches Investigation
NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Abbott Laboratories Employees Credit Union ("ALECU") recently disclosed a data breach that compromised the sensitive personal data of thousands of customers.This data breach has led to concerns over the security...
These Are The Top Health Stocks to Own for Buy-and-Hold Investing
Investors looking for health-related buy-and-hold stocks must look no further than this list. The stocks on this list are market leaders in healthcare, producing sustainable growth with healthy balance sheets, impressive value, and broad market support.
Levi & Korsinsky, LLP Investigates Abbott Laboratories Employees Credit Union ("ALECU") Data Breach
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Abbott Laboratories Employees Credit Union ("ALECU") recently disclosed a data breach that compromised the sensitive personal data of thousands of customers. This data breach has led to concerns over the...
Here's Why You Should Retain ABT Stock in Your Portfolio Now
Investors feel optimistic about Abbott's robust strength in the Diagnostics and Nutrition business. Yet, unfavorable forex impacts are concerning.
My Best Dividend Aristocrats For November 2024
The ProShares S&P 500 Dividend Aristocrats ETF went on a great run during Q3, gaining 11.6% during the quarter. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 39 months of tracking...
ABT's New Trial on Advanced Heart Failure Outcomes Set to Boost Stock
Abbott initiates the TEAM-HF trial to improve outcomes for advanced heart failure.
Tidepool Will Integrate With Abbott's FreeStyle Libre Portfolio for Seamless Cloud-to-Cloud Data
PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool and Abbott collaborate to integrate data, expand patient choice, and improve clinical workflows.
Abbott Laboratories Employees Credit Union (“ALECU”) Data Breach under Investigation by Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Abbott Laboratories Employees Credit Union ("ALECU") recently disclosed a data breach that compromised the sensitive personal data of thousands of customers. This data breach has led to concerns over the...
CORRECTING and REPLACING Tidepool Will Integrate With Abbott's FreeStyle Libre Portfolio for Seamless Cloud-to-Cloud Data
PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool and Abbott partner to integrate data, expand patient choice, and improve clinical workflows.
Source: https://incomestatements.info
Category: Stock Reports